Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • From Policy to Practice: Advanced Practice MAT: Program Development and Evaluation (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the process of developing MAT, along with the most recent results from The ASAM 50th Annual Conference (2019).

    (1 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    The Colorado Legislature has funded a two-year program to expand evidenced-based Medication Assisted Treatment (MAT) programs in two rural counties. The purpose of this program is to increase access to MAT and expand the MAT workforce to treat Opioid Use Disorders, by creating new MAT services in rural areas that are led by nurse practitioners (NPs) or physician assistants (PAs).  NPs and PAs became eligible to prescribe buprenorphine, one important type of MAT, through new Federal legislation in 2016. This presentation will review our entire process of developing this current program, along with our most recent results. Exploring issues from policy origination and development,  legislative expert panel presentation/advisement, and collaborative work in bill passage and legislative engagement for MAT treatment, we will review the process of the development of this current MAT program. Program planning, recruitment and selection of appropriate agencies for MAT program development will be reviewed with data assessment and activities based on types of organizations applying. MAT program implementation and evaluation of three types of MAT service programs in rural counties in Colorado will then be reviewed. Ongoing development needs as programs progress, clinical and administrative needs and collaborative development of programs, including barriers and facilitators encountered, group work for program management, and systems interactions experienced on a local, state, and national level will be discussed so that those interested can develop, from policy to practice, MAT programs in their home areas. Results to date suggest that the MAT Pilot project has increased service availability through new services in two rural counties, including initiation of buprenorphine MAT at an agency that previously provided methadone which increased MAT service provision from (patients seen increased from 89 patients seen in 2017, to 312 patients in 2018), expansion of MAT services at a community mental health center than previously offered MAT on a limited scale(10 patients seen in 2017, to 379 in 2018) and the development of a completely new MAT service provider in an isolated rural town (0 in 2017, to 60 in 2018). Patients served by the MAT Pilot program have been representative of those affected by the opioid epidemic, with the average patient was 25-34 years old, male (53% vs. 47% female), White non-Hispanic (61%, with 33% Latino/Latina), insured through Medicaid (80%), and single (77%). On average patients had used the ED 1.16 times in the past year and rated their health as good, fair, or poor (76.5%) where scores less than “very good” predict negative health outcomes. Patients additional reported a mix of past treatment history, co-morbid physical and mental health conditions, and problem use of prescription opioids, heroin, or both, with reported improvements in these areas in initial ongoing patient follow-up. 


    Learning Objectives:

    1.) Participants will learn effective policy, financing, and marketing strategies for implementing new MAT services in a rural community with no existing MAT options
    2.) Participants will learn effective strategies for implementing NP/PA-led MAT services as part of a team-based approach to opioid treatment within an existing health care organization
    3.) Participants will learn effective strategies for overcoming obstacles, including distance, insurance coverage, continuity of care, and stigma, to program success and increasing patients’ access to care in rural communities


    Tanya R. Sorrell, PhD

    PMHNP-BC

    Tanya R. Sorrell, PhD, PMHNP-BC, Assistant Professor, University of Colorado- Anschutz Medical Campus. My program of research is informed by my clinical work with vulnerable populations with mental health and substance misuse and use disorders across the lifespan. My specific areas of expertise, as PI and Co-PI include community engagement of non-traditional behavioral health and substance use clients, and using community advisory groups to increase health literacy, access to care, and treatment outcomes in behavioral health/substance use services for underserved urban and rural populations. I am currently the Lead Faculty of a state-wide Colorado Senate Bill funded Pilot Medication Assisted Treatment (MAT) Service Delivery Program, a project to enhance access and treatment of substance use in rural Colorado.  I was the PI for a PCORI funded project related to engagement of the community regarding behavioral health needed.  I am the Co-PI for a HRSA funded project that focuses on expanding the behavioral health workforce needs for rural and urban areas of Colorado and New Mexico, using a community engagment, media literacy model. I was awarded the 2017-2018 Junior Scientist Award for my research achievements at the University of Colorado-Anschutz Medical Campus, where I’m an Assistant Professor. I maintain two clinical practices, Sheridan Integrated care clinics (FQHC) in Denver, CO, and Yuma Mental Health in Yuma, AZ serving predominately Latino underserved clients. I serve as the Co-Chair of the Treatment on Demand action group for the Denver County Opiate Task Force, on the Advisory board of the Colorado Leadership Committee for Collective Impact in Substance Use Services (LCCI), the Colorado Consortium for Prescription drug abuse prevention, and the SAMHSA Minority Fellowship Program. My publication record reflects my desires to increase literacy, engagement, and services utilization to improve the overall behavioral health/substance use needs of all underserved populations. 

    Mary Weber

    PhD, PMHNP-BC, FAANP, FAAN

    Mary Weber, PhD, PMHNP-BC, FAANP, FAAN, is a psychiatric nurse practitioner and Endowed Professor in Psychiatric Nursing for the University of Colorado College of Nursing. She has extensive clinical and teaching expertise in chronic mental illness, psychiatric assessment, medication management, and individual/group therapies, having received National Teaching Awards and gained induction into the American Association of Nurse Practitioners and the American Academy of Nursing. She has had grants funded by the Stanley Foundation, HRSA, and SAMHSA, and she has had numerous national presentations and publications. Her research has focused on underserved populations, including the homeless, and those with co-morbid psychiatric, substance, and medical disorders. She was the PI for a SAMHSA funded project, “Nurses Helping Colorado: An SBIRT Training Program.” and was an active participant in a national network of nursing schools implementing similar educational programs to increase the use of SBIRT by nurses in all settings.  She is currently the clinical consultant for a Colorado Senate Bill 74 Implementation of a Medication Assisted Treatment (MAT) Service Delivery Program to exand access to MAT in rural areas of Colorado.  

    Paul F. Cook

    PhD

     Paul Cook, PhD, is a clinical psychologist and an associate professor at the University of Colorado College of Nursing. His primary research area is health behavior change, including smoking cessation, medication adherence, and reducing opioid use.He has collaborated with doctors Sorrell and Weber on several studies related to substance use training and treatment.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Cannabidiol as Medicine: Are We There? (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about research to show whether cannabidiol is ready to be used in clinical practice from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Cannabis is the most abused illicit drug in the world with an estimated 2.5% of the world’s population (180 million) using it regularly (World Drug Report 2017)1. Despite its associated health consequences) (WHO, 2016)2), marijuana as medicine remains the subject of extensive reviews and fierce debates around the globe. Of the 104 cannabinoids present in cannabis, only two-THC and cannabidiol, have been approved as medicine. Neither smoked marijuana or its extract has been approved as medicine. Most recently, cannabidiol (Epidiolex) was approved for the treatment of epilepsy in children. Though research from clinical studies and trials suggests that cannabidiol has a great potential to treat a wide range of clinical conditions including anxiety, depression, Parkinson’s disease, multiple sclerosis and others (Khalsa et al. in press, 2018). Much work is still needed to use it as a medicine at this time. In the meantime, it is of paramount importance that addiction physician is made aware of the adverse medical consequences of marijuana and the current limited research available on medicinal value of cannabis or its cannabinoids that are being promoted as medicine. In this presentation, we will present the currently available research on cannabidiol to show whether cannabidiol is ready to be used in clinical practice as being advocated in the lay literature, and the role of addiction physician/psychiatrist in dealing with issues of medicinal marijuana and/or cannabidiol.

    Learning Objectives:

    1.) The participants will learn about the current most clinical research on cannabidiol  
    2.) The participants will learn about the current research on other cannabinoids related to THC/and cannabidiol and judge whether cannabidiol has been sufficiently developed for use in clinical practice.  
    3.) The participants will learn about the role of addiction physician in dealing with patients who demand cannabidiol for treating any of the unapproved clinical conditions that are being promoted. 


    Jag Khalsa

    PhD, MS

    Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology/medicine, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: jk98p@nih.gov

    Gregory Bunt

    MD, FASAM, FISAM

    Dr. Gregory Bunt graduated medical school in 1983 from NYU School of Medicine, and completed his residency in Psychiatry at the Albert Einstein College of Medicine in 1987. He was among the first to complete the Fellowship in Addiction Psychiatry at NYU School of Medicine (1989), and has since been on the NYU Medical School Faculty in the Division of Alcoholism and Drug Abuse, currently as an Assistant Clinical Professor of Psychiatry. He is a diplomat of the American Board of Psychiatry and Neurology with Special Added Qualifications in Addiction Psychiatry and a Fellow of the International Society of Addiction Medicine.Dr. Bunt is the Immediate Past President of the New York Society of Addiction Medicine and the Immediate Past President of the International Society of Addiction Medicine. He has been the Medical Director for Daytop Village and Daytop International for over 25 years. He has authored over a dozen publications, and speaks nationally and internationally about addiction medicine and therapeutic communities.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Immediate Access Addiction Care: The Evolution of a Low Threshold Bridge Clinic (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about the evolution of Massachusetts General Hospital Bridge Clinic as well as concrete tools to start their own Bridge Clinic from The ASAM 50th Annual Conference (2019).

    The Massachusetts General Hospital Bridge clinic is a multidisciplinary, immediate access low threshold transitional clinic which has provided over 9000 visits to patients since opening in 2016.   Initially a part-time clinic, we have rapidly expanded our model to meet the needs of the complex patient population we service. This has included expanding our hours to  7 days per week, and soon to start evening hours, and enhancing the range of services we offer, including medication management, recovery coaching, optional psychotherapy, psychopharmacology, and peer-support and psychoeducation groups to individuals unable to access care in the community.  From the beginning, our primary goal has been to engage people by “meeting them where they are," and to initiate pharmacotherapy, followed by stabilization and eventual linkage to community based treatment. As we have better understood the needs of our population our strategies for meeting this goal have evolved.  The Bridge clinic was initially established to serve in a complementary role to an inpatient addiction consult team (ACT). However as clinical need has grown we have expanded to partner closely with the emergency department, the obstetrics department, palliative care and oncology, as well as all other outpatient departments. The Bridge Clinic also provides a "consult and return model" for complex patients cared for in the MGH primary care clinics who need stabilization in a low threshold environment and provides  mentorship for newly waivered buprenorphine providers and trainees.  This focus session will describe the evolution of our Bridge Clinic model including lessons learned and the reasons for the changes made, a thorough review of outcomes, and the nuts and bolts needed to start and run this type of clinic model, providing attendees with concrete tools to start their own Bridge Clinic.  

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Learning Objectives:

    1.) Describe the need for urgent access, low threshold models that provide immediate pharmacotherapy and flexible, individualized care for all patients, including those post-overdose, discharge from hospital, detox or incarceration 
    2.) Review the evolution of the Massachusetts General Hospital Bridge model of care, lessons learned, and how we modified the model in response to those lessons
    3.) Develop a blueprint for starting a bridge clinic including how to attain stakeholder buy-in, craft a business plan, determine staffing, design a clinical model, decide what services should be offered, and how to measure outcomes


    Laura G. Kehoe

    MD, MPH, FASAM

    Dr. Kehoe is an Assistant Physician at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School and is board certified in both Internal Medicine and Addiction Medicine.  She attended Tufts University School of Medicine and Boston University School of Public Health and completed her residency in Internal Medicine at Massachusetts General Hospital.   At Massachusetts General Hospital, she is the Medical Director of the Substance Use Disorder Bridge Clinic, an immediate access, urgent care addiction program.   She is actively involved in medical student and resident education as an attending physician on the inpatient Addiction Consult Team (ACT), and she is the co-chair of the hospital-wide Substance Use Disorder Education Committee, where she works with other team members to expand evidence-based treatment of patients with addiction. 

    Outside of MGH, she was the Medical Director of Baycove Treatment Center for Opiate Addictions Methadone Maintenance program and she treats patients as part of a multidisciplinary addiction team at the supportive housing and outpatient non-profit, Right Turn.   Lastly, Dr. Kehoe is a founding member of W.A.T.E.R.town (Watertown Access to Treatment Education and Recovery), a community coalition working to expand prevention, intervention and treatment for people with substance use disorder in Watertown, MA.

    Sarah Wakeman

    MD, FASAM

    Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Guidance From a 24/7 Opioid Treatment Program (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about important elements of attracting and retaining OUD patients in treatment in their community​ from The ASAM 50th Annual Conference (2019).

    (1 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    In October of 2018, Community Medical Services opened the Nation’s first Opioid Treatment on Demand (OTOD) clinic. The concept of this clinic was developed out of necessity to provide access to treatment for clients without time constraints and to facilitate warm hand-off referrals from high-risk touch-points such as hospitals, police, fire departments, emergency medical services, and jails. Since expanding to a 24/7 model, Community Medical Services has conducted over 3500 intakes outside of normal business hours. More importantly, this framework provided the ability to pioneer community initiatives to support referrals at all hours of the day and access to treatment for those in need. The presentation will provide an in-depth analysis around data collected from over a year of operations of OTOD and innovative programs developed with places of high rates of opioid encounters. Attendees will analyze data collected over the first year and a half of operations for the Nation’s first Opioid Treatment on Demand (OTOD) clinic. Attendees will be provided an understanding of the organizational and staffing needs to conduct an OTOD. Audience members will be able to identify and brainstorm gaps in treatment in their own communities that 24/7 services could support for client referrals and system partner support. These system partners can include hospitals, prisons, jails, police, EMS, fire departments, and state family and children services.  Attendees will be able to understand the most important elements of attracting and retaining patients in treatment  in their community who have Opioid Use Disorders.

    Learning Objectives:

    1.) Recite and discuss the Opioid Treatment on Demand Model (OTOD). This will include staffing needs, security, community cohesion, licensure, medication delivery, system partner support, etc.
    2.) Summarize and analyze multiple data points. The number of treatment attempts before in-taking at the OTOD, what time of the day people seek treatment, what day of the week, geographical location, referral source, history of use, etc.. 
    3.) Identify high-risk touch points for people having negative opioid related encounters and how to integrate with the agencies responding to those encounters.


    Charrisa Riggs

    FNP-C

    Charrisa Riggs, FNP-C, Medical Operations Coordinator with Community Medical Services, earned her Master of Science in Nursing from Northern Arizona University in 2015, and her Bachelor of Science in Nursing from Arizona State University in 2008. Mrs. Riggs practices at Community Medical Services, a medication-assisted treatment center, treating patients with opioid use disorders. As a nurse practitioner, Mrs. Riggs also operates her own mobile allergy testing and immunotherapy clinic with a focus on corporate health.   

    Robert Sherrick

    MD, FASAM

    Dr. Robert Sherrick, MD, FASAM, is Chief Medical Officer for Community Medical Services, a company that serves patients through its 30 Opioid Treatment Programs in 8 different states.  Dr. Sherrick completed medical training and residency in Internal Medicine at George Washington University.  After 5 years on the faculty at George Washington,he moved to Montana to join a private practice in Internal Medicine.  Since 1994, Dr. Sherrick has worked at an inpatient addiction treatment facility, Pathways, where he has treated all forms of Substance Use Disorders and has served as the CD Medical Director. Dr. Sherrick has been providing Medication Assisted Treatment for Opioid Use Disorder since 2003, initially in an office setting using buprenorphine and naltrexone.  In 2009, Dr. Sherrick closed his private practice and moved to VA Montana.  Over the next 7 years at VA Montana he developed a state-wide MAT program that was one of the first uses of telemedicine for providing MAT to rural areas.  Dr. Sherrick has been working for Community Medical Services since 2010, providing MAT services with methadone, buprenorphine, and naloxone as well as serving as Northern Medical Director.  He has been Chief Medical Officer for the last year.  He is currently the President of the Northwest Chapter of ASAM. He is Board Certified in Addiction Medicine through the American Board of Preventative Medicine.

    Mark Stavros

    MD, FASAM, FACEP

    Mark Stavros, MD, FASAM, FACEP: Dr. Stavros is board certified in both Emergency Medicine and Addiction Medicine.  He is medical director of Access Recovery Solutions and Gulf Coast Addiction Medicine within Florida focused on the treatment of patients in the community and those in the prison system dealing with opioid use disorder.  He serves as Chief Medical Officer for Maric Healthcare that provides treatment for patients suffering from opioid addiction.  He serves as the Arizona Medical Director for Community Medical Services which treats patients with opiate addiction in Arizona.  He is Clinical Associate Professor and Education Director of Emergency Medicine at FSU College of Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Improving Medical Education In Substance Use Disorders (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning screening, brief Interventions, and referral to treatment (SBIRT) training​ from The ASAM 50th Annual Conference (2019).

    (1 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Despite significant physical, mental and social impairments associated with SUDs, only about 10% of people needing treatment for SUDs receive the help they need. This shortfall is perpetuated by physicians feeling unprepared to make the SUD diagnosis, as well as being unfamiliar with next steps to take once the SUD is identified. Furthermore, many providers do not prefer working with individuals with SUD and pass along negative perceptions to trainees. For example, attitudes of medical trainees farther along in training have been found to be more negative toward individuals with alcohol use disorder than those of first-year medical students, presumably in part due to witnessing stigmatizing behaviors of senior colleagues.  While medication-assisted treatment programs and harm reduction approaches are recently receiving much national attention, there is relatively little focus on improving medical training on SUDs. Curricula lack sufficient instruction and experiences in addiction medicine spanning the continuum of medical education, from medical school through residency and fellowship training programs. Programs that have successfully changed students’ attitudes and skills for treatment of addicted patients continue to be exceptional and limited in focus rather than the general practice in U.S. medical schools.  Several barriers add to the lack of training efforts, including physician attitudes, societal stigma, and skill deficits.  Despite such barriers, however, effective methods exist for incorporating SUD training into each level medical training. Such training may occur in a variety of formats, ranging from online to experiential, and individually to classroom-based. This session will describe recent efforts in providing Screening, Brief Interventions, and Referral to Treatment (SBIRT) training to all medical students, offering buprenorphine training to residents, using standardized patients and interactive sessions to learn and practice Motivational Interviewing skills, and other efforts to provide effective and sustainable SUD education to medical trainees. In addition, we will address skillful methods for addressing provider bias and societal stigma regarding SUD at different levels of medical training. We will invite interactive discussion regarding educational modules and interventions that can be implemented into different levels of medical training curricula, with the goal of creating enduring training opportunities and curricula in each stage of medical education and ensuring a future in which physicians are competent and compassionate in caring for patients with SUD.  

    Learning Objectives:

    1.) Understand existing barriers on educating medical trainees about substance use disorders (SUD). 
    2.) Describe structured methods for incorporating SUD training along the continuum of medical education, including medical schools, residencies, fellowships, and faculty development programs. 
    3.) Identify common misperceptions about SUD and discuss methods for addressing stigma in medical education programs.   


    Thersilla Oberbarnscheidt

    MD PhD

    Thersilla Oberbarnscheidt is a current Fellow at the Western Psychiatric Institute and Clinic at the University of Pittsburgh. She completed her residency at Central Michigan University in Psychiatry and her graduated Medical School from the Christian-Albrechts University in Germany as well as Yale University School of Medicine, USA.  She achieved her PhD in neuroscience with "cum laude" at the Christian-Albrechts University with the thesis  "The effect of phenazone in the acute migraine attack". Her medical background is Internal Medicine in her home country Germany as well as Pain Management. In the US she is a ABPN certified Psychiatrist, currently specilizing in Addiction Psychiatry. Thersilla has a long-standing interest in the field of Addiction and has published numerous articles in the field as well as presented nationally and internationally. Her particular interest is in Marijuana and Opioids.

    Priyanka Amin

    MD

    Priyanka Amin, MD, is a PGY4 psychiatry resident at UPMC Western Psychiatric Hospital. She is currently the Chief Resident for Well-Being Initiatives. After graduation, she will be working as the inpatient attending at the Behavioral Health Intensive Care Unit as well as the psychiatric emergency department at UPMC Western Psychiatric Hospital. She completed undergraduate at Duke University and medical school at the University of Pittsburgh. 

    Jody B. Glance

    MD

    Jody Glance, MD is an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is the Medical Director of Addiction Medicine Services at Western Psychiatric Hospital of UPMC and is a Fellow of the American Society of Addiction Medicine. She serves as the Associate Director of Medical Student Education for the Department of Psychiatry and is involved in many community efforts to educate the public about substance use disorders. Her academic and clinical interests include co-occurring substance use and psychiatric disorders, substance use disorders in pregnancy, and women’s mental health.

    Jin Cheng

    MD

    Jin Cheng MD, Im currently a addiction psychiatry fellow at University of Pittsburgh Medical Center , Western Psychiatric Institute and Clinic. I graduated from Lousiana health science center Shreveport with my medical degree. I've served as the chief resident for the combined family medicine and psychiatry residency at University of Pittsburgh Medical Center. 

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • The Inherited Patient on Sedatives: What to Do Next (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about the risks of sedatives and their management in complex patients from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Introduction: In the shadows of the opioid epidemic lurks the overprescribing and misuse of benzodiazepines and other sedatives. Since the 1960s, benzodiazepines have been cyclically abused. However, from 1996 to 2013, benzodiazepine prescriptions increased by 67%, and overdose deaths involving benzodiazepines increased from 1,135 in 1999 to 8,791 in 2015 (1). Despite these statistics, benzodiazepines and other sedatives continue to be dispensed at an alarming rate. Medicaid expenditures for benzodiazepines increased by almost forty million dollars in a span of 18 years. As a result, many clinicians now face an all-too-common dilemma of inheriting patients who have been prescribed high-dose benzodiazepines and/or other sedatives for a significant length of time. This is a challenge both medically and therapeutically as many patients have co-morbid psychiatric and medical issues, such as anxiety, insomnia, or chronic pain, which may preclude the clinician from quickly switching their medication regimen. Moreover, patients often become attached to their benzodiazepines and are reluctant to change. It is imperative, with the ongoing opioid epidemic, that clinicians are prepared to effectively evaluate and manage patients who are prescribed sedatives. This session will help educate attendees on the risks of sedatives and their management in complex patients.  Session description: This workshop session will begin with a presentation on benzodiazepines that will cover their indications, risk factors for misuse, signs of intoxication and withdrawal, and clinical pearls on how to effectively treat these patients in an outpatient setting. The presentation will be evidence-based and draw from existing medical literature, and it will also include the presenters’ clinical experience with complicated patients. The emphasis will be on clinical issues, such as developing rapport, monitoring benzodiazepine use, recognizing benzodiazepine intoxication and withdrawal, triaging to appropriate level of care, and treating related medical and psychiatric complications. The presenters are experienced clinicians who have been involved in assessing and treating patients with sedative hypnotic use disorders. The presents have also published about benzodiazepines in peer-reviewed journals. After the initial presentation, the presenters will divide the attendees into separate groups. Each group will be assigned a specific case involving sedative misuse reflecting common challenging clinical scenarios. Groups will discuss their case and develop a cohesive treatment plan, which they will then briefly present. Time will be allotted at the end of the workshop for attendees’ questions.  Conclusions: This workshop will provide attendees with evidence-based clinical knowledge to help guide their evaluation and treatment of complex patients with benzodiazepine misuse.  


    Learning Objectives:

    1.) Describe the risks of benzodiazepines and other sedatives.
    2.) Determine how to appropriately and safely prescribe and monitor benzodiazepines and other sedative use.
    3.) Understand how to screen, evaluate, and manage patients suspected of overusing benzodiazepines and other sedatives. 


    Austin Lin

    MD

    Austin Lin, MD is a board-certified Adult and Addiction Psychiatrist. He attended Washington University in St. Louis where he majored in biology and psychology. He then did breast oncology research at Washington University in St. Louis School of Medicine before embarking on to St. George's University School of Medicine. He then attended Harvard South Shore for psychiatry residency, an affiliate program of Harvard Medical School. This was followed by his Addiction Psychiatry fellowship at UT Southwestern Medical Center. He is now the interim adult director for the Trauma and Resilience Center and addiction psychiatrist for the Innovations Clinic at UTHealth. 

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Treatment and Law Enforcement: A Collaborative Approach to Combat the Opioid Epidemic (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about strategies for generating solutions to challenges to collaboration across different sectors from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn about strategies for generating solutions to challenges to collaboration across different sectors. In order to address the growing opioid epidemic in Tucson, Arizona, community stakeholders, including healthcare professionals and law enforcement, created an innovative approach to introduce opioid users to medication assisted treatment. A strategic, coordinated response to connect opioid users to appropriate, evidence-based treatment and services was developed in attempt to reduce the harmful effects of opioid use, such as overdose and blood borne pathogen exposure.  This presentation will discuss the Opioid Deflection/Angel program implemented in Pima County, Arizona. Workshop presenters will discuss the impetus for the Deflection/Angel program and the partnerships necessary for its implementation and evaluation. Presenters will also describe program effectiveness in terms of identification of people with opioid and other substance use problems, linkages to appropriate evidence-based treatment, retention in treatment, and improvements in substance use-related outcomes. Presenters will then describe the step-by-step process involved in the development and implementation of the Deflection/Angel program, including: 1) identifying and connecting key decision-makers; 2) developing partnerships; 3) developing program components; 4) creating implementation procedures; 5) obtaining buy-in from key stakeholders; 6) developing a monitoring and evaluation plan; and 6) obtaining funding. Workshop presenters will teach attendees strategies for generating potential solutions to common challenges and barriers to collaboration across different sectors, such as law enforcement and clinical treatment. Presenters will give particular attention to generating solutions informed by best practices, research, and/or regional data.  


    Learning Objectives:

    1.) Upon completion, participant will be able to understand challenges and possible solutions to creating collaborative partnerships and facilitating cultural shifts in community and law enforcement response to substance use.
    2.) Upon completion, participant will be able to discuss the community relationships between health care providers and law enforcement as they relate to supported response to the opioid epidemic. 
    3.) Upon completion, participant will be able to apply informed strategies within their own community to address the challenges of collaboration across multiple sectors.


    Larry Onate

    MD

    Dr. Onate completed his undergraduate degree and medical degree at the University of Arizona.  He completed his Internship at the University of California San Francisco.  He went on to complete his residency in psychiatry at the University of Arizona in 1993.  He was awarded the American Academy of Child and Adolescent Psychiatry Charter Fellowship in 1991.  Dr. Onate’s work experience includes serving as medical director at the following agencies:  Cottonwood de Tucson, 2010-2017; Southern Arizona Mental Health Corporation Crisis Center, 2000-2010; La Frontera, Inc., 1996-2000; and Desert Hills Center for Family and Youth-Adolescent Inpatient Unit, 1993-1996.  Dr. Onate has served as Medical Director of CODAC MAT 24/7 since 2017.  

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Finding Your Path: Addiction Medicine Career Development (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about options for the Addiction Medicine Professional through case presentations and discussion from The ASAM 50th Annual Conference (2019).

    (1 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    After many years of diligent work by ASAM professionals, Addiction Medicine was recognized by the American Board of Medical Specialties (ABMS) in 2015. The American Board of Preventive Medicine (ABPM), a Member Board of ABMS, sponsored the application for the subspecialty to allow physicians certified by any of the 24 ABMS Member Boards to apply for the new certificate. The first Addiction Medicine Board Certification examination took place in 2017. From 2017 until 2022, physicians will be eligible to certify via either a practice pathway or by completion of a recognized Addiction Medicine fellowship. After 2022, the successful candidate for Board Certification in Addiction Medicine will be required to be fellowship trained. This workshop session will explore career opportunities available to the Addiction Medicine provider. The workshop presenters comprise the 2019 Physicians-In-Training Committee (P-I-T) of ASAM.  The workshop participants will illustrate various practice options for the Addiction Medicine Professional through case presentations and interactive discussion between presenters and participants. The role of the physician within each of the ASAM levels of care will be highlighted. Both currently available practice options and possible future options will be explored.



    Joseph M. Garbely

    DO, DFASAM

    As Vice President of Medical Services and Medical Director at Caron Treatment Centers, Dr. Garbely oversees the following programs and departments: Detoxification Unit, Healthcare Professionals’ Unit, Chronic Pain Program, Pilots' Program, Medical Management, Neurocognitive Services, Psychology, Research, and Spiritual Care. Dr. Garbely received his board certifications through the American Board of Internal Medicine, the American Board of Psychiatry and Neurology, and the American Board of Addiction Medicine. During his tenure at Caron, Dr. Garbely spearheaded a high-level initiative to educate and train physicians in Addiction Medicine through the establishment of the Resident Training Program at Caron Pennsylvania. Dr. Garbely established an American College of Graduate Medical Education (ACGME) accredited Addiction Medicine Fellowship Program at Caron Pennsylvania. As the Addiction Medicine Fellowship Director, Dr. Garbely is a member of the American College of Academic Addiction Medicine. Dr. Garbely is the Chairman of the Physician in Training Committee of the American Society of Addiction Medicine (ASAM), an ex-officio member of the ASAM Board, and a distinguished Fellow of ASAM. Dr. Garbely is a Clinical Associate Professor at Penn State College of Medicine, an Adjunct Associate Professor at Stony Brook School of Medicine, and a member of the medical staff at Reading Hospital. Prior to this, Dr. Garbely served as the Associate Medical Director at Caron Pennsylvania. With 20 years of Addiction Medicine experience, Dr. Garbely has an extensive background in treating substance use disorders, including substance use disorders in healthcare professionals, executives, and pilots. He has worked to develop treatment programs for psychiatric patients involving a 12-Step philosophy.  Dr. Garbely has won teaching awards on the local and national level, including the American Psychiatric Association’s Helen Ruske, MD Award for Excellence in Medical Student Teaching.

    Alma Ramic

    MD

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • First 1000 Days: Transforming Substance Use Disorder Care for the Growing Family (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about clinical models of care for pregnant and parenting women with SUD from The ASAM 50th Annual Conference (2019).

    (1 CME) In this conference recording from the 2019 Annual Conference, you will learn:


    For many women with substance use disorder (SUD), pregnancy can be a motivating time to reduce use of substances and engage in treatment. Following delivery however, relapse is common and rates of overdose in the first postpartum year are higher than during pregnancy. Possible explanations for the rise in overdose post-delivery include loss of access to specialized programming available only during pregnancy, fragmented transitions of care from prenatal to postpartum providers, women discontinuing medication therapy for opioid use disorder after delivery, high rates of postpartum depression and underlying psychiatric disorders, homelessness, lack of social supports, and the stresses of either caring for a new baby or being separated from one’s baby. To address the concerning rise in substance use and overdose among pregnant and postpartum women, Massachusetts General Hospital’s Substance Use Disorder Initiative received pilot funding from the Medicaid Accountable Care Organization in September 2017 to develop a novel clinical model of care for pregnant and parenting women with SUD. The model focused on developing a family-based model of clinical care in which the health of the family unit is central and where pregnancy care seamlessly transitions into postpartum care with the same dedicated multidisciplinary team that has cared for the mother throughout her pregnancy. Designing and implementing this model required engaging stakeholders from across the institution and re-structuring the existing siloed models of care to bring together a leadership team, advisory team, and clinical team that included Obstetrics, Midwifery, Addiction Medicine, Family Medicine, Pediatrics, Social Work, and Psychiatry. During a six-month intensive planning period, we established a novel, co-located, multidisciplinary clinical program where we care for pregnant, postpartum, and parenting women with SUD, their partners, and their infants from conception of pregnancy through early childhood, up to two years of age, or the first 1000 days of life. The HOPE Clinic officially opened April 2018, offering integrated medical and behavioral care including: prenatal care, high-risk obstetrics, office-based addiction treatment, pediatric and adult primary care, perinatal psychiatry, family planning, evidence-based therapy, peer-based and group recovery support, and nursing in a single integrated clinical setting. In this focus session we will highlight the design and development of this novel multidisciplinary perinatal substance use clinic. First, we will discuss key facilitators and barriers to implementation to aid others interested in creating a similar program. Second, we will present the characteristics of clinic participants during our first pilot year. Finally, we will present several case-based and interactive scenarios to discuss the challenges and strengths of providing family-centered co-located care during this vulnerable period.

    Learning Objectives: 

    1.) Recognize trends in overdose rates in the prenatal and postpartum period
    2.) Describe one strategy for engaging key stakeholders in the process of program development
    3.) Demonstrate a collaborative approach to improving care for families affected by substance use disorder 


    Jessica Gray

    MD

    Dr. Jessica Gray is a family medicine physician and addiction specialist in the departments of Medicine at Massachusetts General Hospital (MGH) and Pediatrics in Massachusetts General Hospital for Children (MGHfC). She is associate program director for the MGH Addiction Medicine Fellowship and Clinical Director of the HOPE Clinic at MGH, where she cares for women with substance use disorders and their families from time of conception through the first two years postpartum.  She also sees patients at the MGH Bridge Clinic and is a consultant with the Massachusetts Consultation Service for Treatment of Addiction and Pain (MCSTAP) team, which provides support for primary care providers treating patients with chronic pain and/or substance use disorder.  Prior to coming to MGH Dr. Gray completed her family medicine residency and addiction medicine fellowship at Boston Medical Center and worked as a primary care doctor at a federally qualified health center in Dorchester, Massachusetts. 

    Davida Schiff

    MD, MSc

    Dr. Schiff is a general academic pediatrician and health services researcher focused on understanding how substance use in pregnant and parenting women impacts the health of children and families. She is the Medical Director of the HOPE Clinic (Harnessing support for Opioid and substance use disorder in Pregnancy and Early childhood) at Massachusetts General Hospital, a multidisciplinary program caring for women and families with substance use disorder from the time of conception through the first two years postpartum. Dr. Schiff completed her undergraduate training at Columbia University, medical training at the Boston University School of Medicine, pediatrics residency in the Boston Combined Residency Program at Boston Medical Center and Boston Children’s Hospital, general pediatrics research fellowship at Boston Medical Center, and master’s program in health services research from the Boston University School of Public Health. Her research is focused on improving care for families affected by substance use and her past scholarship has been published in the New England Journal of Medicine, JAMA, Pediatrics, Academic Pediatrics, JSAT, and Substance Abuse, among other journals. She is an Instructor in Pediatrics at Harvard Medical School.


    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Problem Drinking Among Medically Underserved Women: New Horizons in Treatment (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about best approaches to improving access to care and delivering alcohol treatment tailored to medically underserved women from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Among those with alcohol use disorders, women are less likely to obtain treatment, more likely to present with comorbid conditions, and remain in treatment for shorter durations than men. Furthermore, race and ethnicity may  exacerbate gender disparities. For example, by some estimates both Black and Hispanic women have approximately one-quarter the odds of obtaining alcohol services as White women.  This symposium will address best approaches to improving access to care and delivering alcohol treatment tailored to the social needs and cultural influences of three groups of medically underserved women:  1) American Indian and Alaska Native women; 2) African American women; and 3) Hispanic American women.  In addition to providing an overview of risk factors, prevalence, and trends in problem drinking among these groups of women, the session will include an overview of promising programs designed to meet some of their unique treatment needs.  Specific teaching objectives include:  1) to review the latest findings regarding the prevalence and trends in problem drinking among American Indian and Alaska Native women, African American women, and Hispanic American women, and to highlight most salient risk factors for problem drinking in these groups; 2) to identify some of the unique barriers to treatment access among these women and effective approaches to overcoming those barriers; 3) to examine at least one promising treatment program for each group, highlighting treatment elements that are designed to address the unique needs of that group.  Discuss the strengths and limitations of these programs; barriers and possible solutions to implementation and dissemination challenges; 4) to identify gaps in the literature regarding treatment for these groups and recommend most promising directions for future research; and 5) briefly describe ongoing efforts to address the underrepresentation of women from these groups in the alcohol research enterprise and strategies to address this issue.  


    Learning Objectives:

    1.) Summarize latest findings regarding the prevalence and trends in problem drinking among American Indian and Alaska Native women, African American women, and Hispanic American women.  Identify unique risk factors for these groups.
    2.) Identify some of the unique barriers to treatment access among American Indian and Alaska Native women, African American women, and Hispanic American women and effective approaches to overcoming those barriers.
    3.) Describe at least one promising treatment program for each group, highlighting treatment elements that are designed to address the unique needs of that group.  Discuss barriers and possible solutions to implementation challenges;


    Deidra Y. Roach

    MD

    Dr. Roach has more than 30 years of experience in the field of addiction treatment. She currently serves as a Program Director for the National Institute on Alcohol Abuse and Alcoholism where, among other responsibilities, she manages research portfolios addressing the treatment of co-occurring mental health and alcohol use disorders and alcohol-related HIV/AIDS among women. She also serves on the Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) and the NIH Coordinating Committee for Research on Women’s Health. Dr. Roach chairs the Women Drinking, and Pregnancy Work Group of the ICCFASD.

    Dedra Buchwald

    MD

    Dedra Buchwald, MD is a Professor of Medicine in the Elson S. Floyd College of Medicine at Washington State University where she directs the Initiative for Research and Education to Advance Community Health. She is also the founding director of the Partnerships for Native Health, one of the largest research programs on American Indian and Alaska Native health in the nation. This program has worked with over 150 tribal partners and 35 scientists from a wide range of disciplines. New programmatic emphases include rural, Latino, and Native Hawaiian and Pacific Islander populations. Dr. Buchwald has a broad background in public health, population science, and primary care, with special emphases on cultural competence. Her work considers health at the level of the individual, the community, and the health system, using an array of quantitative and qualitative methods. Dr. Buchwald has been the Principal Investigator or Co-Principal Investigator of more than 30 projects funded by NIH and other major organizations and mentored over 50 junior faculty members from diverse backgrounds. 

    Anika Alvanzo

    MD, MS, FASAM, FACP

    Anika Alvanzo, MD, MS is an Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine where she is also the Medical Director of the Johns Hopkins Hospital Substance Use Disorders Consultation Service (SUDS). Dr. Alvanzo is a graduate of the George Washington University School of Medicine and Health Sciences and holds a master's degree in biostatistics from Virginia Commonwealth University. She is board certified in both Internal Medicine and Addiction Medicine. As the Director of the SUDS, Dr. Alvanzo oversees a multidisciplinary consultation service that performs brief behavioral interventions and counseling for hospitalized patients, facilitates linkage to hospital and community-based alcohol and drug treatment programs, provides guidance on the clinical management of substance withdrawal syndromes, and educates patients, families, healthcare professionals and the community to prevent, identify, and treat persons living with addiction. Dr. Alvanzo is also the Director of the Substance Use Disorders Rotation for the Johns Hopkins Medicine-Pediatrics Urban Health and Urban Health Primary Care Residency track programs. Her research interests include gender and race/ethnicity differences in the risk for substance use disorders, integration of technology for screening, brief intervention and referral to treatment in diverse settings and the association between psychological trauma, traumatic stress, and substance use. In particular, she is interested in the mechanisms by which histories of physical and/or sexual violence confer increased risk for substance use disorders and in the development of interventions for co-occurring traumatic stress and substance misuse in women.

    Christina S. Lee

    PhD

    Christina Lee, PhD, is a licensed psychologist whose programmatic research utilizes and disseminates behavioral treatments for substance use to under-served and marginalized populations, with the mission of reducing health inequities related to poor mental and physical health. Dr. Lee’s expertise bridges the areas of intervention science, addiction psychology and health disparities research.  Her primary research studies, funded by NIH, are: (1) developing and testing adapted evidence-based treatments (EBTs) for alcohol and substance use among racial/ethnic minority populations, (2) investigating social determinants of substance use behaviors among marginalized populations, (3) investigating mechanisms of change and psychological processes underlying addiction and its treatment, and (4) using interdisciplinary and multi-level models to implement and disseminate EBTs for substance use (alcohol, opioids).  Dr. Lee received a NIH National Research Service Award (NRSA) as a PhD student, and completed a NIH funded post-doctoral fellowship at the Center for Alcohol and Addiction Studies at Brown University. Dr. Lee is on the editorial boards of the Journal of Consulting and Clinical Psychology and of Cultural Diversity: Ethnic and Minority Psychology. In 2013, Dr. Lee received the Kenerson Faculty Scholarship Award at Northeastern for her interdisciplinary research and community service, where she co-established an integrated primary care practice at the South End Community Health Center in Boston, where she currently consults to the Suboxone Support Program. In 2015, she was selected as a NIH Fellow in Randomized Behavioral Clinical Trials (NHLBI). She has been a MINT (Motivational Interviewing Network of Trainers) member since 2006 and is certified in Dialectical Behavior Therapy. 

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.